戈沙妥珠单抗后线治疗晚期恶性肿瘤的近期效果及安全性  

Short-term efficacy and safety of sacituzumab govitecan in posterior-line therapy for advanced malignant tumors

作　　者：汪洋 皇甫超男 王志宁 Wang Yang;Huangfu Chaonan;Wang Zhining(Department of Oncology,Nanjing BenQ Hospital,Nanjing 210000,China)

机构地区：[1]南京明基医院肿瘤科,南京210000

出　　处：《肿瘤研究与临床》2025年第3期186-189,共4页Cancer Research and Clinic

摘　　要：目的探讨戈沙妥珠单抗(SG)在晚期恶性肿瘤后线治疗中的效果及不良反应。方法回顾性病例系列研究。回顾性分析2023年7月至12月南京明基医院收治的20例多线治疗后应用SG治疗的晚期恶性肿瘤患者的临床病理资料,评估近期疗效及治疗相关不良事件(TRAE)。结果20例患者中,男性7例,女性13例,中位年龄[M(Q1,Q3)]60.0(53.8,72.5)岁,既往接受抗肿瘤治疗方案中位线数为4.5(3.3,6.0)线,SG中位治疗时间为52.5(35.8,72.5)d。SG治疗后部分缓解3例(15.0%),分别为乳腺癌、阴道鳞状细胞癌及子宫内膜癌,疾病稳定10例(50.0%),疾病进展7例(35.0%);客观缓解率为15.0%(3/20),疾病控制率为65.0%(13/20)。因不能耐受不良反应停药2例(10.0%)。TRAE发生率为75.0%(15/20),其中≥3级TRAE发生率为10.0%(2/20),分别为中性粒细胞减少性发热和室性心律失常。结论SG在晚期恶性肿瘤后线治疗中具有一定的疗效,且安全性可控。Objective To explore the efficacy and adverse reactions of sacituzumab govitecan(SG)in the posterior-line therapy for advanced malignant tumors.Methods A retrospective case series study was conducted.The clinicopathological data of 20 patients with advanced malignant tumors who were treated with SG after multiple lines of treatment in Nanjing BenQ Hospital From July to December 2023 were retrospectively analyzed.The short-term efficacy and treatment-related adverse events(TRAE)were evaluated.Results Among the 20 patients,there were 7 males and 13 females,the median age[M(Q1,Q3)]was 60.0(53.8,72.5)years old,the median line of previous anti-tumor regimens was 4.5(3.3,6.0)lines,and the median duration time of SG treatment was 52.5(35.8,72.5)days.After SG treatment,there were 3 cases(15.0%)with partial response,including breast cancer,vaginal squamous cell carcinoma and endometrial carcinoma,10 cases(50.0%)with stable disease and 7 cases(35.0%)with progressive disease.The objective response rate was 15.0%(3/20),and the disease control rate was 65.0%(13/20).Two cases(10.0%)were discontinued due to intolerable adverse reactions.The incidence of TRAE was 75.0%(15/20),of which the incidence of≥grade 3 TRAE was 10.0%(2/20),including neutropenic fever and ventricular arrhythmia.Conclusions SG has a certain therapeutic effect and controllable safety in the posterior-line therapy for advanced malignant tumors.

关 键 词：肿瘤 免疫轭合物 抗体 单克隆 人源化 治疗结果 不良反应 戈沙妥珠单抗 后线治疗 

分 类 号：R730.5[医药卫生—肿瘤]